Physician profile
Kinga A Powers
NPI 1609913979
$13,739.76
in general payments reported to CMS, 2019-2025
18 companies · $3,529 in 2025
The $3,529 reported for 2025 was more than what 87% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $260 · 2021: $5,270 · 2022: $2,499 · 2023: $1,876 · 2024: $306 · 2025: $3,529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,643 · Food and Beverage: $1,649 · Long Term Medical Supply Or Device Loan: $918 · Consulting Fee: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,643.45 |
| Food and Beverage | $1,649.26 |
| Long Term Medical Supply Or Device Loan | $918.42 |
| Consulting Fee | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,863.50 | 2021-2025 | Da Vinci Surgical System |
| Medtronic, INC. | $3,107.70 | 2021-2025 | Progrip, Signia |
| Apollo Endosurgery US INC | $1,383.58 | 2022 | |
| Integra Lifesciences Corporation | $1,185.49 | 2023-2025 | Integra, Cytal, Micromatrix |
| W. L. Gore & Associates, INC. | $1,182.72 | 2020-2023 | Gore Bio-A Tissue Reinforcement |
| Stryker Corporation | $675.13 | 2025 | 1788 |
| Nico Corporation | $500.00 | 2023 | |
| Tela Bio, INC. | $170.59 | 2022 | |
| Novo Nordisk INC | $162.04 | 2023 | Wegovy |
| Conmed Corporation | $134.61 | 2024-2025 | Airseal |
| Ethicon US, LLC | $93.48 | 2022 | |
| Acell, INC. | $71.72 | 2020 | |
| Davol INC. | $63.14 | 2020 | |
| Innocoll Pharmaceuticals Limited | $58.32 | 2021-2022 | |
| Kerecis Limited | $36.43 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $19.12 | 2022 | |
| Daiichi Sankyo INC. | $16.78 | 2022 | |
| Merck Sharp & Dohme LLC | $15.41 | 2025 | Bridion |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kinga Powers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.